A large proportion of the approximately 8 million acute medically ill patients each year in the United States are at risk for venous thromboembolism (VTE) ([@bib1]). Hospitalization is considered the single most important risk factor for developing these events ([@bib2]), and the risk of VTE continues beyond hospitalization, especially within the first 6 weeks after discharge ([@bib3]). Although the relationship between VTE and atherothrombosis/arterial thromboembolism has been known for some time due to the shared mechanisms of inflammation, hypercoagulability, and endothelial injury inherent to both disease processes and due to common patient-level risk factors, such as obesity, dyslipidemia, and tobacco use ([@bib4],[@bib5]), it has only recently been appreciated that medically ill patients are also at increased risk of arterial thromboembolic events in the post-hospital discharge period ([@bib6],[@bib7]). Retrospective data also reveal that extended duration of a prophylactic dose of a direct oral anticoagulant in medically ill patients may reduce the risk of fatal and major arterial thromboembolism by 30% to 50% ([@bib6],[@bib7]).

The previously reported MARINER trial (A Study of Rivaroxaban \[[JNJ-39039039](https://clinicaltrials.gov/ct2/show/NCT02111564){#interref0025}\] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients) ([NCT02111564](https://clinicaltrials.gov/ct2/show/NCT02111564){#intref0015}) ([@bib8]), randomized medically ill patients with additional risk factors for VTE to extended-duration rivaroxaban (10 mg once daily for 45 days or 7.5 mg once daily for those with a creatinine clearance between 30 and 50 ml/min) or placebo after excluding those at high risk of bleeding. Although the trial did not demonstrate a reduction in the primary endpoint of symptomatic VTE and VTE-related death, key secondary efficacy endpoints revealed a 56% reduction in symptomatic VTE and a 27% reduction in symptomatic VTE and all-cause mortality. The lower 7.5 mg dose of rivaroxaban used in patients with moderate renal insufficiency was found to be ineffective ([@bib8]), unlike the dose of 10 mg, which had previously been demonstrated to be effective in the MAGELLAN (Venous Thromboembolic Event \[VTE\] Prophylaxis in Medically Ill Patients; [NCT00571649](https://www.clinicaltrials.gov/ct2/show/NCT00571649){#interref0020}) study of extended thromboprophylaxis in medically ill patients ([@bib9]). A pre-specified secondary endpoint of the trial was fatal and major venous and arterial thromboembolic events ([@bib8]). Therefore, this exploratory analysis focused on whether rivaroxaban could reduce the incidence of fatal and major thromboembolic events in patients treated with 10 mg daily of rivaroxaban compared with placebo when given to acutely ill medical patients at the time of discharge for 45 days.

Methods {#sec1}
=======

Study design {#sec1.1}
------------

The MARINER protocol and study results have been reported previously ([@bib8],[@bib10]). The protocol was approved by local ethics committees, and all subjects provided written informed consent. Briefly, MARINER was a multicenter, prospective, randomized, double-blind, placebo-controlled, event-driven study that evaluated rivaroxaban (10 mg daily in patients with creatinine clearance \[CrCl\] ≥50 ml/min or 7.5 mg daily with CrCl 30 to \<50 ml/min at baseline) versus placebo for 45 days beyond hospital discharge to prevent symptomatic VTE and VTE-related death in acutely ill medical patients. Eligible patients were 40 years of age or older, were hospitalized for at least 3 and no more than 10 consecutive days prior to randomization for a specific acute medical illness, and had other risk factors for VTE. Other VTE risk factors were demonstrated by a total modified IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) VTE risk score of ≥4 or VTE risk score of 2 or 3 with D-dimer \>2× the upper limit of normal. Patients received thromboprophylaxis during the index hospitalization with low-molecular-weight heparin or unfractionated heparin. Patients with an increased risk of bleeding were excluded from the study. The primary hypothesis was that rivaroxaban was superior to placebo for the prevention of the composite of symptomatic VTE (lower extremity deep vein thrombosis and nonfatal pulmonary embolism \[PE\]) and VTE-related death (death due to PE or death in which PE could not be ruled out). The primary hypothesis of this exploratory analysis was that rivaroxaban was superior to placebo for the prevention of the pre-specified composite of symptomatic VTE, myocardial infarction (MI), nonhemorrhagic stroke, and cardiovascular (CV) death in the stratum of patients with a baseline CrCl ≥50 ml/min receiving the 10 mg dose of rivaroxaban.

Statistical methods {#sec1.2}
-------------------

The point estimate for the hazard ratio (HR) and corresponding 95% confidence interval (CI) for the 10 mg rivaroxaban dose versus placebo were provided based on the Cox proportional hazards model. Patients were analyzed according to the treatment group they were randomized to, regardless of the actual treatment received. All statistical tests were interpreted at a nominal (without adjustment for multiplicity) 2-sided significance level of 0.05, and all CIs at a nominal 2-sided level of 95%. The Kaplan-Meier method was used to summarize the time-to-event analyses.

Efficacy and safety outcomes {#sec1.3}
----------------------------

The efficacy outcome of the composite of symptomatic VTE, MI, nonhemorrhagic stroke, and CV death was a pre-specified secondary endpoint, and individual outcomes were verified by objective testing and autopsy reports, where available using standardized definitions ([@bib8]). The principal safety outcome of major bleeding was based on the International Society on Thrombosis and Haemostasis bleeding criteria and included fatal bleeding, bleeding into a critical organ, or bleeding that led to a drop of ≥2 g/dl of hemoglobin or a transfusion of 2 U or more of blood. Bleeding events were analyzed based on time from randomization to the first occurrence. All endpoints were adjudicated by a blinded clinical events committee.

Results {#sec2}
=======

Baseline characteristics {#sec2.1}
------------------------

A total of 4,909 patients were assigned to the rivaroxaban 10 mg group (baseline CrCl ≥50 ml/min) and 4,913 patients to matching placebo and are included in the intent-to-treat (ITT) population. The ITT analysis set included all randomized patients who had valid informed consent. Baseline characteristics were well balanced between treatment groups ([Table 1](#tbl1){ref-type="table"} ). The mean age of this population was 67.8 years, 55.5% were men, and 96.5% were white. The most frequently reported admitting diagnosis for patients overall was heart failure with reduced ejection fraction ≤45% (37.2%) and the mean duration of hospitalization was 6.7 ± 2.4 days. Overall, 52.0% of patients had a baseline CrCl level ≥80 ml/min and 47.9% had a baseline CrCl 50 to \<80 ml/min with a mean baseline creatine clearance of 87.8 ml/min. At baseline, aspirin was used in 51.9% of patients; a statin was used by 41.7%. A history of reduced or preserved ejection fraction heart failure (47.7%), coronary artery disease (31.6%), diabetes (28.7%), and hyperlipidemia (20.0%) were also common in the population. A history of cancer was reported by 8.3% of patients, while patients with active cancer undergoing chemotherapy were excluded. Total modified IMPROVE VTE risk factor scores of 2, 3, and ≥4 were reported for 35.8%, 28.4%, and 35.8% of patients, respectively.Table 1Characteristics of Patients at Baseline (ITT)Rivaroxaban 10 mg (n = 4,909)Placebo (n = 4,913)Male55.355.7Mean age, yrs67.867.7White race96.396.7Mean BMI, kg/m^2^29.529.3Reason for hospitalization Heart failure37.437.0 Respiratory insufficiency or exacerbation of chronic obstructive pulmonary disease27.628.0 Ischemic stroke15.515.7 Infectious disease17.917.7 Inflammatory disease1.51.7Mean duration of index hospitalization, days6.76.7D-dimer \>2× upper limit of normal during the index hospitalization68.768.7Mean baseline CrCl87.987.8Baseline aspirin51.949.1Current or former smoker48.248.3Baseline statin41.941.4Baseline U.S.-approved thromboprophylaxis71.271.5History of hypertension78.278.8History of diabetes29.527.9History of heart failure47.947.5History of coronary artery disease32.131.1History of hyperlipidemia20.519.6History of cancer8.08.7IMPROVE VTE risk factor score 235.536.0 329.327.4 ≥435.136.4[^1][^2]

Efficacy and safety outcomes {#sec2.2}
----------------------------

The composite endpoint of symptomatic VTE, MI, nonhemorrhagic stroke, and CV death occurred in 1.28% of patients randomized to rivaroxaban and in 1.77% of those on placebo (HR: 0.72; 95% CI: 0.52 to 1.00; p = 0.049) ([Table 2](#tbl2){ref-type="table"} ). All incidence of the components of the composite endpoint, except MI, numerically tended to favor rivaroxaban. Symptomatic lower-extremity deep vein thrombosis and symptomatic nonfatal PE showed greater risk reduction with rivaroxaban with a relative risk reduction of 80% (HR: 0.20; 95% CI: 0.04 to 0.91) and 62% (HR: 0.36; 95% CI: 0.12 to 1.14), respectively ([Table 2](#tbl2){ref-type="table"}). Kaplan-Meier curves for the composite of symptomatic VTE, MI, nonhemorrhagic stroke, and CV death are presented in the [Central Illustration](#undfig2){ref-type="fig"} .Table 2Time to First Occurrence of Composite Outcome and Components (ITT)EndpointRivaroxaban 10 mgPlaceboRivaroxaban 10 mg vs. PlaceboHR (95% CI)[∗](#tbl2fnlowast){ref-type="table-fn"}p Value[†](#tbl2fndagger){ref-type="table-fn"}Composite of symptomatic VTE (DVT and nonfatal PE), MI, nonhemorrhagic stroke, CV death63/4,909 (1.28)87/4,913 (1.77)0.72 (0.52--1.00)0.049Symptomatic lower extremity DVT2/4,909 (0.04)10/4,913 (0.20)0.20 (0.04--0.91)---Symptomatic nonfatal PE4/4,909 (0.08)11/4,913 (0.22)0.36 (0.12--1.14)---MI13/4,909 (0.26)8/4,913 (0.16)1.62 (0.67--3.92)---Nonhemorrhagic stroke13/4,909 (0.26)24/4,913 (0.49)0.54 (0.28--1.06)---CV death39/4,909 (0.79)42/4,913 (0.85)0.93 (0.60--1.44)---[^3][^4][^5][^6]Central IllustrationMajor Efficacy and Safety Outcomes Over Time**(A)** Time to first occurrence of composite: venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death up to day 45 (rivaroxaban 10 mg daily vs. placebo; intention to treat). Includes all data from randomization to day 45 (inclusive). Patients who do not have events are censored on the minimum of last visit before or on death or day 45. **(B)** Time to first occurrence of major bleeding on-treatment (rivaroxaban 10 mg daily vs. placebo; safety population). On-treatment includes all data from randomization to 2 days after the last dose of the study drug (inclusive). Subjects who do not have events are censored on the minimum of last visit before or on death, or last dose +2 days. CI = confidence interval; HR = hazard ratio.

The bleeding analysis used the safety population, which for the 10 mg dose included 4,890 in both the rivaroxaban and placebo groups for a total of 9,780 patients. Major bleeding occurred in 13 (0.27%) and 9 (0.18%) patients in the rivaroxaban and placebo groups, respectively (HR: 1.44; 95% CI: 0.62 to 3.37; p = 0.398) ([Table 3](#tbl3){ref-type="table"} ). When evaluated by type of major bleeding, a greater proportion of patients receiving 10 mg rivaroxaban than placebo had major bleeding events with a fall in hemoglobin of ≥2 g/dl (0.22% and 0.12%, respectively) and transfusion of \>2 U of packed red blood cells (or whole blood) than patients in the placebo group (0.16% and 0.06%, respectively). There were 2 critical site bleeds in each group, and 2 fatal bleeds in the rivaroxaban group. A Kaplan-Meier analysis of the timing of major bleeding occurrence is shown in the [Central Illustration](#undfig2){ref-type="fig"}.Table 3Time to First Occurrence of Major Bleeding Event, On-Treatment (Safety Analysis Set)EndpointRivaroxaban 10 mgPlaceboRivaroxaban 10 mg vs. PlaceboHR (95% CI)[∗](#tbl3fnlowast){ref-type="table-fn"}p Value[†](#tbl3fndagger){ref-type="table-fn"}ISTH major bleeding13/4,890 (0.27)9/4,890 (0.18)1.44 (0.62--3.37)0.398 Fall in hemoglobin of ≥2 g/dl11/4,890 (0.22)6/4,890 (0.12)1.83 (0.68--4.95)--- Transfusion of ≥2 U of packed red blood cells or whole blood8/4,890 (0.16)3/4,890 (0.06)2.66 (0.71--10.04)--- Critical site2/4,890 (0.04)2/4,890 (0.04)1.00 (0.14--7.10)--- Fatal outcome2/4,890 (0.04)0/4,890NANA[^7][^8][^9][^10]

Discussion {#sec3}
==========

This analysis demonstrates that compared with placebo, extended-duration thromboprophylaxis with low-dose rivaroxaban (10 mg daily) started after hospital discharge leads to a significant 28% reduction in the combined risk of fatal and major thromboembolic events without a significant increase in major bleeding in hospitalized medically ill patients. This benefit appears to begin after the first week of treatment and continues until the end of study at 45 days. There was a 0.49% absolute risk reduction of efficacy events and a 0.09% absolute increase in the risk of major bleeding, suggesting a net clinical benefit.

A meta-analysis of arterial thrombosis (including MI and ischemic stroke) of older studies involving ∼11,000 medically ill inpatients receiving heparin-based prophylaxis did not find a reduction of these events compared with control subjects (odds ratio: 1.95; 95% confidence interval: 0.89 to 4.27) ([@bib11]). The authors concluded that arterial thrombotic events appeared to be under-reported in trials of venous thromboprophylaxis, and they recommended systematic monitoring of such events in future trials. In the MARINER study, data on arterial events were captured using a standardized data collection form, and all suspected events were centrally adjudicated using pre-specified criteria. Although exploratory, our analysis suggests that extended thromboprophylaxis with rivaroxaban in medically ill patients may lead to reductions in arterial thromboembolic events (primarily ischemic stroke) as well as a reduction in symptomatic VTE. Such a finding is in line with the results of the APEX trial ([@bib12]), which in post hoc analyses revealed a ∼30% reduction in fatal and irreversible ischemic events (including PE, MI, nonfatal ischemic stroke, or CV death) without an increase in fatal or intracranial hemorrhage, and a ∼50% reduction in ischemic stroke with betrixaban compared with placebo ([@bib6],[@bib7]). A recent pooled analysis of both the MARINER and MAGELLAN trials of extended thromboprophylaxis with the 10 mg dose of rivaroxaban also revealed a significant 22% reduction in all-cause mortality and major thromboembolic events, including symptomatic VTE, MI, and nonhemorrhagic stroke (1.80% vs. 2.31%; HR: 0.78; 95% CI: 0.63 to 0.97; p = 0.024), without an increase in critical site or fatal bleeding ([@bib13]).

The association between VTE and arterial thromboembolic disease has been well-established ([@bib5],[@bib14]). Underlying common mechanisms of both VTE and arterial thromboembolism suggest that primary thromboprophylaxis using an established anticoagulant regimen, possibly against a background of antiplatelet therapy and given for a sufficient duration, can be effective in reducing both types of events. An analysis of MARINER data in the subset of patients receiving rivaroxaban plus aspirin, although not randomized for aspirin use and hypothesis generating, suggested greater efficacy with rivaroxaban plus aspirin in reducing symptomatic VTE and VTE-related death ([@bib15]). In the COMPASS (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease; [NCT01776424](https://clinicaltrials.gov/ct2/show/NCT01776424){#interref0030}) trial, a very large study that compared 2.5 mg twice daily of rivaroxaban plus 100 mg aspirin daily with 100 mg aspirin daily alone in patients with chronic coronary artery disease or peripheral artery disease, rivaroxaban plus aspirin significantly reduced the incidence of CV death, stroke, and MI by 24% ([@bib16]). This dose of rivaroxaban would be predicted to produce trough levels similar to those achieved with 10 mg once daily ([@bib17],[@bib18]); this finding was supported by data from the MARINER pharmacokinetic substudy in patients receiving the 10 mg dose ([@bib9]).

Our findings may have important implications for the population of medically ill patients now that rivaroxaban is approved for extended post-hospital discharge thromboprophylaxis in at-risk medically ill patients in the United States. A previous benefit/risk assessment of a low-bleed risk subpopulation of the MAGELLAN trial revealed that extended thromboprophylaxis with the 10 mg dose of rivaroxaban would lead to 21 fewer fatal and major thromboembolic events per 10,000 patients at the expense of 9 more critical site or fatal bleeds, with a number needed to treat of 481 and number needed to harm of 1,061 ([@bib19]). In the large population of at-risk medically ill patients each year, this strategy would have the potential to prevent 12,000 fatal and major thromboembolic events annually at the cost of one-fourth to one-half that number of major or fatal bleeds ([@bib19]).

Study limitations {#sec3.1}
-----------------

Limitations of this study include its exploratory nature, because the MARINER study failed to meet its primary efficacy endpoint. We cannot exclude potential under-reporting of arterial thromboembolic events as the trial was powered to assess the risk of VTE, although this is unlikely because a standardized case report form was used with careful study oversight of outcomes and central adjudication of all of these events. In addition, the composite endpoint was driven primarily by a reduction in symptomatic VTE and ischemic stroke. Although event rates may be considered low (\<2.0%), the time-to-event curves suggest that events continued to accumulate after the study period of 45 days such that we cannot exclude the possibility that rivaroxaban continues to reduce these events over a longer period of time. Our study also excluded subjects with moderate renal insufficiency because the reduced dose chosen (7.5 mg) was deemed inadequate. However, a recent study has demonstrated efficacy in this population with 10 mg daily of rivaroxaban with a favorable benefit risk profile ([@bib9]). As approximately 50% of our study population had baseline aspirin use, an important antithrombotic synergy between prophylactic dose rivaroxaban and antiplatelet therapy cannot be excluded, and there are mechanistic implications of such a synergistic antithrombotic strategy that may lead to reductions in CV outcomes ([@bib15],[@bib16]).

Conclusions {#sec4}
===========

Our analysis suggests that in at-risk medically ill patients who are discharged from the hospital, extended-duration rivaroxaban at the 10 mg daily dose leads to a significant risk reduction in a composite of fatal and major thromboembolic events---including symptomatic VTE, MI, nonhemorrhagic stroke, and CV death---without a significant increase in major bleeding, compared with placebo. These data suggest that in properly selected patients at risk for VTE and at low risk for bleeding, that extended-duration rivaroxaban at 10 mg has a favorable benefit risk profile.Perspectives**COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS:** Hospitalized medically ill patients remain at risk of venous and arterial thromboembolism, especially within the first 6 weeks after discharge. Treatment with rivaroxaban (10 mg once daily) for up to 45 days beyond discharge of patients at higher risk of thromboembolism and lower risk of bleeding reduces the incidence of fatal and major thromboembolism without increasing major bleeding.**TRANSLATIONAL OUTLOOK:** Prospective studies of patients hospitalized with coronavirus disease-2019 pneumonia are needed to confirm the benefit and safety of extended antithrombotic therapy in that specific subset of medically ill patients.
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[^1]: Values are % or mean (where indicated). Note: intention-to-treat (ITT): all randomized patients who had valid signed informed consent. U.S.-approved thromboprophylaxis includes enoxaparin, dalteparin, and heparin. Patients who have both U.S.-approved and other baseline use of thromboprophylaxis are included in the U.S.-approved thromboprophylaxis category.

[^2]: BMI = body mass index; CrCl = creatine clearance; IMPROVE VTE = International Medical Prevention Registry on Venous Thromboembolism venous thromboembolism model.

[^3]: Values are n/N (%) unless otherwise indicated. CV death includes VTE-related death. All events were adjudicated by the clinical event committee. Intention-to-treat (ITT): all randomized patients who had valid signed informed consent.

[^4]: CI = confidence interval; CV = cardiovascular; DVT = deep vein thrombosis; HR = hazard ratio; MI = myocardial infarction; PE = pulmonary embolism; VTE = venous thromboembolism.

[^5]: HRs (95% CIs) are from Cox proportional hazards model with treatment as the only covariate.

[^6]: The p value (2-sided) for superiority of rivaroxaban versus placebo from Cox proportional hazards model.

[^7]: Values are n/N (%) unless otherwise indicated. All adjudicated by the clinical event committee. Safety analysis set: all intention-to-treat patients who take at least 1 dose of study drug.

[^8]: ISTH = International Society on Thrombosis and Haemostasis; NA = not applicable; other abbreviations as in [Table 2](#tbl2){ref-type="table"}.

[^9]: HRs (95% CIs) are from Cox proportional hazards model with treatment as the only covariate.

[^10]: p value (2-sided) for superiority of rivaroxaban vs. placebo from Cox proportional hazards model.
